Allied Market Research published a report, titled, “Cancer Gene Therapy Market 𝐛𝐲 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 (𝐆𝐞𝐧𝐞 𝐈𝐧𝐝𝐮𝐜𝐞𝐝 𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲, 𝐎𝐧𝐜𝐨𝐥𝐲𝐭𝐢𝐜 𝐕𝐢𝐫𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲, 𝐆𝐞𝐧𝐞 𝐓𝐫𝐚𝐧𝐬𝐟𝐞𝐫), 𝐛𝐲 𝐄𝐧𝐝 𝐔𝐬𝐞𝐫 (𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥𝐬, 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐜𝐞𝐧𝐭𝐞𝐫𝐬, 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐈𝐧𝐬𝐭𝐢𝐭𝐮𝐭𝐞𝐬): 𝐆𝐥𝐨𝐛𝐚𝐥 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐲 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐚𝐧𝐝 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭, 2020-2030.” According to the report, the global cancer gene therapy industry generated $1.4 billion in 2020, and is expected to reach $11.4 billion by 2030, witnessing a CAGR of 23.3% from 2021 to 2030.
Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer. Owing to the high success rate during the preclinical and clinical trials, cancer gene therapy has gained popularity. There are many techniques used for cancer gene therapy, for example, a procedure where the mutated gene is being replaced with a healthy gene or the inactivation of the gene whose function is abnormal. Cancer gene therapy is an approach to cancer treatment, where genetically engineered vectors such as viruses are used to transfer or replace a mutated gene (that is causing cancer) with a healthy gene. This technique can be used for both the prevention and treatment of disease. The most commonly used techniques for the treatment using cancer gene therapy includes oncolytic virotherapy, gene transfer, and gene-induced immunotherapy
𝐅𝐨𝐫 𝐑𝐢𝐠𝐡𝐭 𝐏𝐞𝐫𝐬𝐩𝐞𝐜𝐭𝐢𝐯𝐞, 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐚𝐭 : : https://www.alliedmarketresearch.com/request-sample/2605
𝐂𝐨𝐯𝐢𝐝-19 𝐒𝐜𝐞𝐧𝐚𝐫𝐢𝐨
⮞ During the Covid-19 pandemic, there has been significant decline in diagnosis of six major types of cancer such as breast, colorectal, lung, pancreatic, gastric, and oesophageal cancers. This led to reduction in revenue of the global cancer gene therapy market revenue.
⮞ The Centers for Disease Control and Prevention (CDC) and other organizations recommended the postponement of cancer screening and other elective surgeries. However, therapies and surgeries were conducted in emergency situations in a secure environment.
𝐁𝐲 𝐫𝐞𝐠𝐢𝐨𝐧, North America accounted for the maximum Cancer Gene Therapy Market share in 2020, owing to the high prevalence rate of cancer, presence of high disposable income, and high funding for R&D activities associated with cancer gene therapy. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, attributable to a rise in the incidence rate of cancer, an increase in a government initiative to improve healthcare infrastructure, and owing to rise in the number of people prone to various chronic diseases. In addition, approval and launch of cancer gene therapy products can positively influence market expansion in developed countries, such as Japan, Australia, and New Zealand are the major factors for the growth of the cancer gene therapy market.
𝐃𝐨 𝐘𝐨𝐮 𝐇𝐚𝐯𝐞 𝐀𝐧𝐲 𝐐𝐮𝐞𝐫𝐲 𝐎𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐪𝐮𝐢𝐫𝐞𝐦𝐞𝐧𝐭? 𝐀𝐬𝐤 𝐭𝐨 𝐎𝐮𝐫 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐄𝐱𝐩𝐞𝐫𝐭: https://www.alliedmarketresearch.com/purchase-enquiry/2605
𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬
⮞ Bristol Myers Squibb Co.
⮞ Novartis
⮞ Amgen Inc.
⮞ Glaxosmithkline PLC
⮞ Kayropharma Therapeutics
⮞ Gilead Sciences
⮞ Adapta Immue
⮞ Genulex Corporation
⮞ SynerGene Therapeutics
⮞ Shanghai Sunway Biotech
𝐅𝐑𝐄𝐐𝐔𝐄𝐍𝐓𝐋𝐘 𝐀𝐒𝐊𝐄𝐃 𝐐𝐔𝐄𝐒𝐓𝐈𝐎𝐍𝐒?
Q1. Which are the top companies to hold the market share in Cancer Gene Therapy?
Q2. Which is the largest regional market for Cancer Gene Therapy?
Q3. What are the upcoming trends of the Cancer Gene Therapy Market in the world?
Q4. What is the market value of the Cancer Gene Therapy Market report in the forecast period?
Q5. Does the Cancer Gene Therapy report provide Value Chain Analysis?
Q6. What is the market value of the Cancer Gene Therapy Market in 2020?
𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐁𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠 : https://www.alliedmarketresearch.com/purchase-enquiry/2605
⮞ Hip Replacement Market https://www.alliedmarketresearch.com/hip-replacement-market-A17084
⮞ Tendon Repair Market https://www.alliedmarketresearch.com/tendon-repair-market-A17088
⮞ Mastopexy market https://www.alliedmarketresearch.com/mastopexy-market-A16849
⮞ Thyroid Ablation Devices Market https://www.alliedmarketresearch.com/thyroid-ablation-devices-market-A13571